Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain

Benjamin Guy Trist; Courtney Jade Wright; Alejandra Rangel; Louise Cottle; Asheeta Prasad; Nanna Møller Jensen; Hjalte Gram; Nicolas Dzamko; Poul Henning Jensen; Deniz Kirik

doi:10.1038/s41531-024-00830-y

Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain

Benjamin Guy Trist, Courtney Jade Wright, Alejandra Rangel, Louise Cottle, Asheeta Prasad, Nanna Møller Jensen, Hjalte Gram, Nicolas Dzamko, Poul Henning Jensen, Deniz Kirik

Department of Biomedicine - Forskning og uddannelse, Vest

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

Abstract

Assays for quantifying aggregated and phosphorylated (S129) human α-synuclein protein are widely used to evaluate pathological burden in patients suffering from synucleinopathy disorders. Many of these assays, however, do not cross-react with mouse α-synuclein or exhibit poor sensitivity for this target, which is problematic considering the preponderance of mouse models at the forefront of pre-clinical α-synuclein research. In this project, we addressed this unmet need by reformulating two existing AlphaLISA ® SureFire ® Ultra™ total and pS129 α-synuclein assay kits to yield robust and ultrasensitive (LLoQ ≤ 0.5 pg/mL) quantification of mouse and human wild-type and pS129 α-synuclein protein. We then employed these assays, together with the BioLegend α-synuclein aggregate ELISA, to assess α-synuclein S129 phosphorylation and aggregation in different mouse brain tissue preparations. Overall, we highlight the compatibility of these new immunoassays with rodent models and demonstrate their potential to advance knowledge surrounding α-synuclein phosphorylation and aggregation in synucleinopathies.

Original language	English
Article number	217
Journal	npj Parkinson's Disease
Volume	10
Issue	1
ISSN	2373-8057
DOIs	https://doi.org/10.1038/s41531-024-00830-y
Publication status	Published - Dec 2024

Access to Document

10.1038/s41531-024-00830-yLicence: CC BY

Cite this

@article{457337ba63c340e7b50e1bed0819c7d7,

title = "Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain",

abstract = "Assays for quantifying aggregated and phosphorylated (S129) human α-synuclein protein are widely used to evaluate pathological burden in patients suffering from synucleinopathy disorders. Many of these assays, however, do not cross-react with mouse α-synuclein or exhibit poor sensitivity for this target, which is problematic considering the preponderance of mouse models at the forefront of pre-clinical α-synuclein research. In this project, we addressed this unmet need by reformulating two existing AlphaLISA {\textregistered} SureFire {\textregistered} Ultra{\texttrademark} total and pS129 α-synuclein assay kits to yield robust and ultrasensitive (LLoQ ≤ 0.5 pg/mL) quantification of mouse and human wild-type and pS129 α-synuclein protein. We then employed these assays, together with the BioLegend α-synuclein aggregate ELISA, to assess α-synuclein S129 phosphorylation and aggregation in different mouse brain tissue preparations. Overall, we highlight the compatibility of these new immunoassays with rodent models and demonstrate their potential to advance knowledge surrounding α-synuclein phosphorylation and aggregation in synucleinopathies. ",

author = "Trist, {Benjamin Guy} and Wright, {Courtney Jade} and Alejandra Rangel and Louise Cottle and Asheeta Prasad and Jensen, {Nanna M{\o}ller} and Hjalte Gram and Nicolas Dzamko and Jensen, {Poul Henning} and Deniz Kirik",

note = "{\textcopyright} 2024. The Author(s).",

year = "2024",

month = dec,

doi = "10.1038/s41531-024-00830-y",

language = "English",

volume = "10",

journal = "npj Parkinson's Disease ",

issn = "2373-8057",

publisher = "Springer Nature",

number = "1",

}

Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain. / Trist, Benjamin Guy; Wright, Courtney Jade; Rangel, Alejandra et al.
In: npj Parkinson's Disease , Vol. 10, No. 1, 217, 12.2024.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review

TY - JOUR

T1 - Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain

AU - Trist, Benjamin Guy

AU - Wright, Courtney Jade

AU - Rangel, Alejandra

AU - Cottle, Louise

AU - Prasad, Asheeta

AU - Jensen, Nanna Møller

AU - Gram, Hjalte

AU - Dzamko, Nicolas

AU - Jensen, Poul Henning

AU - Kirik, Deniz

PY - 2024/12

Y1 - 2024/12

N2 - Assays for quantifying aggregated and phosphorylated (S129) human α-synuclein protein are widely used to evaluate pathological burden in patients suffering from synucleinopathy disorders. Many of these assays, however, do not cross-react with mouse α-synuclein or exhibit poor sensitivity for this target, which is problematic considering the preponderance of mouse models at the forefront of pre-clinical α-synuclein research. In this project, we addressed this unmet need by reformulating two existing AlphaLISA ® SureFire ® Ultra™ total and pS129 α-synuclein assay kits to yield robust and ultrasensitive (LLoQ ≤ 0.5 pg/mL) quantification of mouse and human wild-type and pS129 α-synuclein protein. We then employed these assays, together with the BioLegend α-synuclein aggregate ELISA, to assess α-synuclein S129 phosphorylation and aggregation in different mouse brain tissue preparations. Overall, we highlight the compatibility of these new immunoassays with rodent models and demonstrate their potential to advance knowledge surrounding α-synuclein phosphorylation and aggregation in synucleinopathies.

AB - Assays for quantifying aggregated and phosphorylated (S129) human α-synuclein protein are widely used to evaluate pathological burden in patients suffering from synucleinopathy disorders. Many of these assays, however, do not cross-react with mouse α-synuclein or exhibit poor sensitivity for this target, which is problematic considering the preponderance of mouse models at the forefront of pre-clinical α-synuclein research. In this project, we addressed this unmet need by reformulating two existing AlphaLISA ® SureFire ® Ultra™ total and pS129 α-synuclein assay kits to yield robust and ultrasensitive (LLoQ ≤ 0.5 pg/mL) quantification of mouse and human wild-type and pS129 α-synuclein protein. We then employed these assays, together with the BioLegend α-synuclein aggregate ELISA, to assess α-synuclein S129 phosphorylation and aggregation in different mouse brain tissue preparations. Overall, we highlight the compatibility of these new immunoassays with rodent models and demonstrate their potential to advance knowledge surrounding α-synuclein phosphorylation and aggregation in synucleinopathies.

UR - http://www.scopus.com/inward/record.url?scp=85209807995&partnerID=8YFLogxK

U2 - 10.1038/s41531-024-00830-y

DO - 10.1038/s41531-024-00830-y

M3 - Journal article

C2 - 39516469

SN - 2373-8057

VL - 10

JO - npj Parkinson's Disease

JF - npj Parkinson's Disease

IS - 1

M1 - 217

ER -

Novel tools to quantify total, phospho-Ser129 and aggregated alpha-synuclein in the mouse brain

Abstract

Access to Document

Other files and links

Fingerprint

Cite this